Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis

Area of Science:

• Neuroimmunology
• Clinical Pharmacology
• Evidence Synthesis

Background:

• Multiple Sclerosis (MS) treatments include diverse agents like immunosuppressants, immunomodulators, and monoclonal antibodies.
• Direct comparative trials are limited, creating uncertainty regarding the relative effectiveness of these MS therapies.
• A comprehensive summary of direct and indirect treatment comparisons is needed to clarify therapeutic options.

Purpose of the Study:

• To evaluate the relative efficacy and acceptability of eleven MS treatments against placebo or active comparators.
• To rank multiple sclerosis (MS) treatments based on effectiveness and overall risk-benefit balance.
• To provide evidence-based guidance for clinicians and patients managing MS.

Main Methods:

• Systematic literature search of Cochrane Database, Cochrane MS Group Trials Register, and FDA reports up to February 2012.
• Inclusion of randomized controlled trials (RCTs) assessing 11 specific MS treatments in adults.
• Data synthesis using pairwise and Bayesian network meta-analysis, with evidence quality assessed by GRADE.

Main Results:

• High-quality evidence shows natalizumab and interferon beta-1a (Rebif) effectively reduce relapses in relapsing-remitting MS (RRMS) within 24 months.
• Moderate evidence suggests natalizumab and interferon beta-1a (Rebif) may decrease disability progression in RRMS short-term.
• No treatments demonstrated efficacy in preventing disability progression for patients with progressive MS.

Conclusions:

• Natalizumab and interferon beta-1a (Rebif) show superior short-term relapse prevention in RRMS but carry potential long-term risks.
• Interferon beta-1b (Betaseron) and mitoxantrone likely reduce RRMS relapses, though evidence quality is moderate.
• Efficacy for progressive MS disability progression is lacking for all evaluated treatments; long-term data beyond two years is uncertain.